First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate...

Full description

Bibliographic Details
Main Authors: Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Kei Ogata, Masahiko Kajiwara, Satoshi Itano, Yoshinori Yokokura, Taizo Yamaguchi, Hiroshi Kawano, Norito Matsukuma, Hideya Suga, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Cancer Medicine
Subjects:
carcinoma
hepatocellular
nonalcoholic steatohepatitis
sequential therapy
sorafenib
Online Access:https://doi.org/10.1002/cam4.4367

Internet

https://doi.org/10.1002/cam4.4367

Similar Items